TCRT_OUT_1 [2025-04-02 08:33:57 -0400] 2803 Bytes | 774 tokens | Cum: 774 tkns (9.68% of 8k)
==========================================================================

You're the expert here today. So, I pulled together a bunch of data for you to look over real fast. I'm looking at high-performance stocks today and Alaunos Therapeutics (TCRT) hit my radar screen, up to 2.53 from a prev close of 2.16 Do you think its got more juice or is it lacking potential? It's 8:33:57 AM on Wed Apr 02, 2025 -0400 and I have to decide: buy or sell!

--- COMPANY PROFILE ---
Company: Alaunos Therapeutics (TCRT)
IPO: 2005-08-24 (19 Years Ago)
Market Cap: $3,458,704
Shares Outstanding: 1,600,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.

Here's the first list of news for Alaunos Therapeutics:

C1 - Oct-11-24 08:57AM - Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy
C2 - May-15-24 10:55PM - TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q1 2024
C3 - Apr-08-24 12:52PM - TCRT Stock Earnings: Alaunos Therapeutics Misses EPS for Q4 2023
C4 - Dec-18-23 07:57AM - Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?
C5 - Nov-14-23 07:56AM - Why Is Alaunos Therapeutics (TCRT) Stock Up 14% Today?
C6 - Nov-14-23 07:56AM 07:30AM - Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives
C7 - Aug-14-23 04:05PM - Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives
C8 - Jun-29-23 07:00AM - Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies

Prior AI Reports for TCRT:
1. 2025-04-01 – Score: 55 – Target: 3.3300 – Highs: – / – / –
rising-volume-amid-financial-distress-a-paradoxical-scenario

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Alaunos Therapeutics (TCRT)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

TCRT_OUT_3 [2025-04-02 08:34:03 -0400] 1100 Bytes | 267 tokens | Cum: 1043 tkns (13.04% of 8k)
==========================================================================

Showing C1 (chunk 1 of 2): C1:
**Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy**
Date: Oct-11-24 08:57AM
Source: (TipRanks)
URL: https://finance.yahoo.com/news/alaunos-therapeutics-ends-licensing-deal-125737537.html

The latest announcement is out from Alaunos Therapeutics ((TCRT)).

Alaunos Therapeutics, Inc. has decided to terminate its amended licensing agreement with Precigen, Inc. for developing neoantigen T-cell receptors to treat solid tumor cancers, signaling a shift in strategic priorities. The original agreement, in place since 2018, will end following Alaunos’s assessment of its business goals and the impending patent expiration of the Sleeping Beauty gene transfer platform in 2026. Despite this, Alaunos is actively pursuing its intellectual property rights for certain T-cell receptors and exploring various strategic options, including mergers and partnerships, to advance its business in

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TCRT_OUT_5 [2025-04-02 08:34:07 -0400] 278 Bytes | 89 tokens | Cum: 1236 tkns (15.45% of 8k)
==========================================================================

Showing C1 (chunk 2 of 2): terests.

See more insights into TCRT stock onTipRanks’ Stock Analysis page.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TCRT_OUT_7 [2025-04-02 08:34:08 -0400] 594 Bytes | 161 tokens | Cum: 1451 tkns (18.14% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-01T17:05:47Z - 12 Health Care Stocks Moving In Tuesday's Intraday Session - bioAffinity Technologies (NASDAQ:BIAF),...
A2 - 2025-03-28T11:03:20Z - North American Morning Briefing: Tariff Jitters -2-...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

TCRT_OUT_9 [2025-04-02 08:34:09 -0400] 1098 Bytes | 329 tokens | Cum: 1782 tkns (22.27% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**12 Health Care Stocks Moving In Tuesday's Intraday Session - bioAffinity Technologies (NASDAQ:BIAF), CARISMA Therapeutics (NASDAQ:CARM)**Date: 2025-04-01Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/04/44591128/12-health-care-stocks-moving-in-tuesdays-intraday-sessionGainers Reshape Lifesciences RSLS stock moved upwards by 488.1% to $2.12 during Tuesday's regular session. The market value of their outstanding shares is at $7.0 million. bioAffinity Technologies BIAF stock increased by 236.5% to $0.87. The market value of their outstanding shares is at $13.6 million. As per the news, the Q4 earnings report came out yesterday. Alaunos Therapeutics TCRT shares moved upwards by 55.1% to $2.28. The market value of their outstanding shares is at $3.6 million. Nutex Health NUTX shares moved upwards by 53.55% to $72.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TCRT_OUT_11 [2025-04-02 08:34:11 -0400] 1084 Bytes | 325 tokens | Cum: 2109 tkns (26.36% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-02-01T18:17:44Z - Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
B2 - 2024-01-10T18:06:18Z - Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
B3 - 2024-01-05T13:03:11Z - Why Dermata Therapeutics Shares Are Trading Higher By Over 57%; Here Are 20 Stocks Moving Premarket
B4 - 2023-12-19T18:34:55Z - Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
B5 - 2023-12-19T13:09:17Z - Why Motus GI Holdings Shares Are Trading Lower By Around 46%; Here Are 20 Stocks Moving Premarket
B6 - 2023-12-18T18:05:04Z - Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

TCRT_OUT_13 [2025-04-02 08:34:15 -0400] 1102 Bytes | 307 tokens | Cum: 2418 tkns (30.23% of 8k)
==========================================================================

Showing B1 (chunk 1 of 3): B1:
**Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/news/24/02/36895069/why-c-h-robinson-shares-are-trading-lower-by-over-12-here-are-other-stocks-moving-in-thursdays-mid-dShares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter financial results.
C.H. Robinson Worldwide posted adjusted earnings of 50 cents per share, missing market estimates if 81 cents per share. The company’s quarterly sales came in at $4.20 billion versus estimates of $4.34 billion.
C.H. Robinson Worldwide shares dipped 12.6% to $73.49 on Thursday.
Here are some other stocks moving in today's mid-day session.
Gainers

Minim, Inc. (NASDAQ: MINM) shares climbed 57.3% to $6.45. David

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TCRT_OUT_15 [2025-04-02 08:34:16 -0400] 1076 Bytes | 259 tokens | Cum: 2775 tkns (34.69% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S4 - 2025-03-31 10-K Item 7. Management's Discussion and Analysis of Fin Cond and Results of Oper

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes appearing else...

S5 - 2025-03-31 10-K Item 7. Management's Discussion and Analysis of Fin Cond and Results of Oper

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes appearing else...

S6 - 2024-11-14 10-Q PART IFIN INFO

Item 1. Condensed Fin Stmnts

Alaunos Therapeutics, Inc.

COND BAL SHEETS

(unaudited)

(in thousands, except share and per share data)

September 30,

December 31,

ASSETS:

Curr assets:

Cash and cash equiv

$...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

TCRT_OUT_17 [2025-04-02 08:34:17 -0400] 1098 Bytes | 228 tokens | Cum: 3005 tkns (37.56% of 8k)
==========================================================================

Showing S4 (chunk 1 of 6): S4:
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K. In addition to historical financial information, the following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results, levels of activity, performance or achievements could differ materially from those contained in or implied by any forward-looking statements. Factors that could cause or contribute to these differences include those under Risk Factors included in Part I, Item 1A and under Special Note Regarding Forward-Looking Statements or in other parts of this Annual Report on Form 10-K. All share amounts pre

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TCRT_OUT_19 [2025-04-02 08:34:24 -0400] 1098 Bytes | 265 tokens | Cum: 3272 tkns (40.90% of 8k)
==========================================================================

Showing S4 (chunk 2 of 6): sented in this Item 7 give effect to the 1-for-15 reverse stock split and the 1-for-10 second reverse stock split of our outstanding shares of common stock that occurred on January 31, 2024 and July 17, 2024, respectively.

Overview

On October 10, 2024, we announced our continued progress and evaluation of our internally developed small molecule oral obesity program. The aim of this program is to develop a drug for obesity with a differentiated profile relative to currently marketed and in development oral and injectable products. We have also operated as a clinical-stage oncology-focused cell therapy company developing adoptive TCR-T cell therapy, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. On August 14, 2023, we announced a strategic reprioritization of our business and wind down of our TCR-T Library Phase 1/2 Trial. In

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TCRT_OUT_21 [2025-04-02 08:34:30 -0400] 1098 Bytes | 258 tokens | Cum: 3638 tkns (45.48% of 8k)
==========================================================================

Showing S4 (chunk 3 of 6): connection with the reprioritization, we have reduced our workforce during the third and fourth quarters of 2023, and we continue working to reduce costs in order to extend our cash runway. We continue to explore strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. We engaged Cantor Fitzgerald Co., or Cantor, to act as strategic advisor for this process.

We have not generated any product revenue and have incurred significant net losses in each year since our inception. For the year ended December 31, 2024, we had a net loss of $4.6 million, and as of December 31, 2024, we have incurred approximately $920.4 million of accumulated deficit since our inception in 2003. We expect to continue to incur significant operating expenditures and net losses for the foreseeable fu

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TCRT_OUT_23 [2025-04-02 08:34:41 -0400] 4635 Bytes | 1342 tokens | Cum: 5141 tkns (64.26% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+-----------------------+-----------------------+
| Volume: 5,410,726 | Perf Month: 37.58% | Option/Short: No / No | Sales Y/Y TTM: 80.00% |
+---------------------+-----------------------+-----------------------+-----------------------+
| Avg Volume: 102.00K | Perf Quarter: 17.39% | Short Float: 3.75% | ROE: -111.83% |
+---------------------+-----------------------+-----------------------+-----------------------+
| Rel Volume: 395.25 | Index: - | Short Ratio: 0.51 | ROI: -571.06% |
+---------------------+-----------------------+-----------------------+-----------------------+
| RSI (14): 74.26 | Market Cap: 3.46M | Short Interest: 0.05M | Sales Surprise: - |
+---------------------+-----------------------+-----------------------+-----------------------+
| ATR (14): 0.19 | Shs Outstand: 1.60M | Beta: -1.01 | EPS Surprise: -14.29% |
+---------------------+-----------------------+-----------------------+-----------------------+
| SMA20: 40.61% | Shs Float: 1.38M | Sales Q/Q: 300.00% | P/E: - |
+---------------------+-----------------------+-----------------------+-----------------------+
| SMA50: 34.60% | Inst Own: 4.51% | Sales past 5Y: - | Earnings: - |
+---------------------+-----------------------+-----------------------+-----------------------+
| SMA200: -22.39% | Insider Own: 13.75% | Employees: - | |
+---------------------+-----------------------+-----------------------+-----------------------+
| Perf Week: 34.10% | Insider Trans: -1.35% | Debt/Eq: 0.00 | |
+---------------------+-----------------------+-----------------------+-----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Alaunos Therapeutics, Inc. (TCRT) by Groenewald Ferdinand (VP, Finance) on 2025-03-29
- Employee Stock Option (right to buy): 3000 shares at $0 (D)

Inside Trans: Alaunos Therapeutics, Inc. (TCRT) by Lackey Melinda (Legal & Administration) on 2025-03-29
- Employee Stock Option (right to buy): 1000 shares at $0 (D)

Inside Trans: Alaunos Therapeutics, Inc. (TCRT) by Hogue Dale Curtis Jr. (See Remarks) on 2025-03-29
- Employee Stock Option (right to buy): 3000 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -1127000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 2.16
Average Volume: 256634.91
30-Day High: 2.16
30-Day Low: 1.4301

[Detailed Financials: Q3 2024]
- Total Assets: $3,550,000.0
- Total Liabilities: $826,000
- Total Equity: $2,724,000.0
- Current Assets: $3,550,000.0
- Current Liabilities: $826,000

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.7

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-781,000

[Detailed Financials: Q2 2024]
- Total Assets: $4,678,000.0
- Total Liabilities: $907,000
- Total Equity: $3,771,000.0
- Current Assets: $4,678,000.0
- Current Liabilities: $907,000

[Income Statement: Q2 2024]
- Revenue: $4,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.71

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-1,681,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

TCRT_OUT_25 [2025-04-02 08:34:43 -0400] 676 Bytes | 167 tokens | Cum: 5572 tkns (69.65% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

TCRT_IN_27 [2025-04-02 08:34:44 -0400] 126 Bytes | 29 tokens | Cum: 5629 tkns (70.36% of 8k)
==========================================================================

====================================
[2025-04-02 08:34:44] # Analysis Completed
Elapsed Time: 46.81 seconds